

Supplemental Table S1. Antibodies used in this study.

Antibodies	Supplier	Cat.	Usage
Nqo1	CST	#3187	Western Blotting
β-Actin	MBL	M177-3	Western Blotting
Keratin 14	abcam	ab7800	Immunohistochemistry
Keratin 10	abcam	ab76318	Immunohistochemistry
Nqo1	CST	#62262	Immunohistochemistry
Anti-mouse IgG, HRP-linked Antibody	CST	#7076	Western Blotting
Anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 555 Conjugate)	CST	#4409	Immunohistochemistry
Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 555 Conjugate)	CST	#4413	Immunohistochemistry
Anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate)	CST	#4408	Immunohistochemistry
Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate)	CST	#4412	Immunohistochemistry

Supplemental Table S2. Normal human epidermal keratinocytes used in this study.


<b>Supplier</b>	<b>Sex</b>	<b>Age</b>	<b>Race</b>	<b>Tissue</b>	<b>Lot number</b>	
PromoCell	female	31	Caucasian	skin		
	female	32	Caucasian	breast	Pooled	433Z033
	female	51	Caucasian	eyelid		
PromoCell	female	56	Caucasian	abdomen	Single	451Z0141
BIOPREDIC International	female	23	Caucasian	abdomen	Single	KER110016

Supplemental Table S3. The concentration of 10H2DA in royal jelly.


Royal jelly	Lot	10H2DA (%)	Method
Lyophilized raw royal jelly	YDP-M-180120	4.65	HPLC
Lyophilized raw royal jelly	YDP-M-190801	4.86	HPLC
Lyophilized raw royal jelly	YDP-M-200225	4.58	HPLC
Lyophilized protease-treated royal jelly	YRP-M-181030	4.06	HPLC

Supplemental Table S4. Primer pairs used in this study

Symbol	Gene name	Forwead, Sequence (5'->3')	Reverse, Sequence (5'->4')
AHR	Aryl hydrocarbon receptor	TGGTTGTGATGCCAAAGGAAGAA	ACTGGACCAAGTCCATCGG
AQP3	Aquaporin 3	CCGTGACCTTGCCATGTGCTT	TTGTCGGCGAAGTGCCAGATTG
CAPN1	Calpain-1	TTCGAGCCCAAACAAGGAGGG	AGAGCACTTGCTCATCGGGG
CASP14	Caspase-14	CAGCCCACAAACCATCCAAC	GTAAGCGATGTATCCCTTACCGT
CAT	Catalase	AATGCTTCAGGGCCGCCTT	ACTCGAGCACGGTAGGGACA
CD44	CD44 molecule	AGTGGTTTGGCAACAGATGGC	GAGGCTGCAGCTGTCCCTGT
CEMIP	Cell migration inducing hyaluronidase 1	GGAGCCGGCCATCATCAGAC	GGGAAGGTTCCACCACTGGC
CLDN1	Claudin 1	GTCTTGACTCCTGCTGAATCTG	CACCTCATCGTCTCCAAGCAC
COL17A1	Collagen type XVII alpha 1 chain	CAGGACCTGTCACCACCATC	CGTACCCGAAGTCCGTAAG
COL4A1	Collagen type IV alpha 1 chain	GAGTGCCTGGAAAGGACGGG	GGTGTCTGGCAAGCCCAT
CTSH	Cathepsin H	TCATGGATGTCTAACGACCGT	GGTCCCATTGTTGTGGCG
CYP1A1	Cytochrome P450 family 1 subfamily A member 1	GATTGAGCACTGTCAGGAGAAC	ATGAGGCTCCAGGAGATAGCAG
FNI	Fibronectin 1	CAGCAGTACGGCCACCAAGA	ACGGTGGCTGGTCACAGG
FOXO3	Forkhead box O3	TCGAGAGCTCCCCGGACAAA	GGATGGAGTTCTCCAGCCG
GCLC	Glutamate-cysteine ligase catalytic subunit	TTCACACTGCCGAGGTCAA	CTTGTAAAGGTACTGAAGCGAGGGT
HAS3	Hyaluronan synthase 3	ACCAACCGAGTCCTGAGCCT	TGGTTGAGCCACCGGAGGTA
IVL	Involucrin	CCAGGCCAGGTCCAAGACAT	CTGGACACTGCGGGTGGTTA
KRT1	Keratin 1	TGACAAGGTGAGGTTCTGGAG	AGTTGGTCACTCTCCTTCGG
KRT10	Keratin 10	AGTCCAACCTGGCCTGAAAC	AGCTGCACACAGTAGCGACC
KRT14	Keratin 14	TGCCGAGGAATGGITCTTCACC	GCAGCTCAATCTCAGGTTCTG
KRT5	Keratin 5	GCTGCCTACATGAACAAGGTGG	ATGGAGAGGACCACTGAGGTGT
LAMA5	Laminin subunit alpha 5	GAGGCTTTGAACCGGGCAGT	TCCTGCTTCCTTGCAGGGC
LOR	Loricrin cornified envelope precursor protein	GTCTGCGGAGGTGGTTCCTCT	TGCTGGGTCTGGTGGCAGATC
MMP2	Matrix metallopeptidase 2	TGAGGGCGCTCTGTCTCCTG	TCAGGTATTGCACTGCCAACTC
NQO1	NAD(P)H quinone dehydrogenase 1	CCTGCCATTCTGAAAGGCTGGT	GTGGTGATGGAAAGCACTGCCT
Nrf2	Nuclear factor, erythroid 2 like 2	CCAACTACTCCCAGGTTGCC	GTGACTGAAACGTAGCCGAAGA
OCLN	Occludin	ATGGCAAAGTGAATGACAAGCGG	CTGTAACGAGGCTGCCTGAAGT
SIRT3	Sirtuin 3	CCACCTGCACAGTCTGCCAA	CAGCGGCTCCCCAAAGAACAA
SOD1	Superoxide dismutase 1	GCACACTGGTGGTCCATGAAA	CAAGCCAACGACTTCCAGCG
SOD2	Superoxide dismutase 2	CCCAAAGGGAGTTGCTGGAA	CCAAGCCAACCCCAACCTGA
SPTLC1	Serine palmitoyltransferase long chain base subunit 1	GCAGTGTGAAGGAAAAGTGC	CAGTGCTCTCTCCAGTTGTAGG
TGFB1	Transforming growth factor beta 1	GTTGTGCGGCAGTGGTGAG	CCGGTAGTGAACCCGTTGATG
TGM1	Transglutaminase 1	GAACGACTGCTGGATGAAGAGG	CTTGATGGACTCCACAGAGCAG
ZO1	Zonula occludens-1	GTCCAGAACATCTCGGAAAAGTGCC	CTTCAGCGACCATAACCAACC




**Supplemental Figure S1. Comparison of the gene expression pattern in keratinocytes following stimulation with RJ or keratinocyte differentiation inducer, CaCl<sub>2</sub>.** Two major clusters, A1 and A2, were observed before (0 d) and after (3 d) stimulation. With CaCl<sub>2</sub>, there were two clusters, B1 and B2. B1 contained the keratinocyte differentiation markers *Krt1* and *Krt10*. On the other hand, nRJ-treated keratinocytes expressed another characteristic of gene expression that was classified into clusters C1 and C2. In cluster C1, both stratum spinosum and granular layer related genes such as *Flg* and *Lvl* were observed.



**Supplemental Figure S2. Changes in Nrf2 downstream genes following stimulation with nRJ**

Keratinocytes (pooled) were treated with 1 mg/ml nRJ for 3 days. Expression of *Gclc*, *Hmox1*, and *Txn* was analyzed using real-time PCR. Data represent mean  $\pm$  SEM,  $n = 3-4$ , \*\* $p < 0.01$ , vs. Control (Cont), Student's *t*-test.



**Supplemental Figure S3. Induction of NQO1 expression in keratinocytes (derived from 23y donor and 56 y donor) was comparable among different lots of nRJ.**

Keratinocytes were treated with 1 mg/ml nRJ (RJ1 Lot YDP-M-180120, RJ2 Lot YDP-M-190801, and RJ3 Lot YDP-M-200225) for 3 days. NQO1 mRNA expression was analyzed by real-time PCR. Data represent the mean  $\pm$  SEM, n=3.